[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Central China Fuwai Hospital of Zhengzhou University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100601690","plasma-biomarkers-and-platelet-morphology-of-extracorporeal-cardiopulmonary-resuscitation-100601690",false,"NCT07113769","Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation","Explore Plasma Biomarkers and Platelet Morphological Signatures for Predicting Prognosis in Patients With Extracorporeal CardioPulmonary Resuscitation (ECPR) Using Multi-omics and Platelet Morphology Analysis","ECPR","Inclusion Criteria:\n\n1. Age between 18 and 70 years old (the age limit can be relaxed if the patient has good organ function and a good neurological prognosis after evaluation).\n2. The cardiac arrest is witnessed, and bystanders perform traditional cardiopulmonary resuscitation (CPR), and the time interval from the occurrence of cardiac arrest to the start of traditional CPR is no more than 5 minutes.\n3. The causes of cardiac arrest are reversible, such as cardiogenic, pulmonary embolism, severe hypothermia, drug poisoning, trauma, acute respiratory distress syndrome, etc.\n4. After 20 minutes of traditional CPR, there is no restoration of spontaneous circulation or hemodynamic instability, or the restoration of spontaneous circulation occurs, but the spontaneous heart rhythm cannot be maintained.\n5. The informed consent has been signed.\n\nExclusion Criteria:\n\n1. Infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, etc.\n2. Hematological diseases, such as hematological malignancies, aplastic anemia, idiopathic thrombocytopenic purpura (ITP), etc.\n3. Malignant tumors in other systems except the hematological system.\n4. Patients who have received massive plasma or platelet transfusions during hospitalization or recently.","ALL","18 Years",{"count":20,"type":21},130,"ESTIMATED","1 Month","OBSERVATIONAL","Extracorporeal cardiopulmonary resuscitation (ECPR) constitutes a pivotal emergency intervention for cardiac arrest (CA) patients. However, current eligibility criteria and prognostic assessment metrics remain substantially limited, relying predominantly on clinical symptoms and physical signs while lacking objective biomarker data. Integrating reproducible, highly sensitive, and specific proteinaceous and metabolic indicators with ultrastructural platelet alterations may hold significant implications for both ECPR administration and prognostication in CA. Therefore, the purpose of this study is to identify the plasma proteomic and metabolomic characteristics of patients with refractory cardiac arrest before and after ECPR treatment, as well as the characteristics of platelet morphological and structural changes, to search for potential specific markers that can predict CA patients who may benefit from ECPR so as to optimize treatment selection.",[26,27],"ExtraCorporeal Membrane Oxygenation (ECMO)","Cardiac Arrest","RECRUITING","2026-03-19",{"date":31,"type":32},"2026-03-23","ACTUAL",{"date":34,"type":32},"2025-09-01",{"date":36,"type":21},"2026-12-30",{"name":38,"class":39},"Central China Fuwai Hospital of Zhengzhou University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100620893","multicenter-randomized-controlled-trial-rct-and-efficacy-evaluation-system-study-on-surgical-innovation-strategies-for-neonatal-complex-congenital-heart-disease-100620893","NCT07363538","Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease","Inclusion Criteria:\n\n1. Neonates diagnosed with TAPVC, CoA\u002FIAA, TGA, PA\u002FIVS, or severe PS via pre-admission cardiac echocardiography;\n2. Patients and families demonstrating high compliance, willing to sign informed consent forms and agree to complete one year of follow-up and related examinations.\n\nExclusion Criteria:\n\n1. Preterm infant (gestational age \\\u003C 36 weeks at birth);\n2. Low birth weight (weight \\\u003C 2.5 kg);\n3. Concurrent severe extracardiac anomalies or complex cardiac malformations;\n4. Preoperative respiratory or circulatory instability requiring emergency surgery.","7 Days",{"count":49,"type":21},738,"INTERVENTIONAL",[52],"NA","There remains controversy regarding the optimal timing of surgical treatment for neonatal CCHD (Complex Congenital Heart Disease). Based on the established national multi-center database for surgical treatment of congenital heart disease and the prenatal-postnatal integrated diagnosis and treatment model, this study will conduct a multi-center RCT (Randomized Controlled Trial) to explore the optimal surgical timing for neonatal CCHD. It will also develop innovative comprehensive treatment strategies for critically ill neonatal CCHD patients, use RCT data to evaluate treatment efficacy and establish an evaluation system. This system will be gradually promoted nationwide, aiming to reduce the incidence of perioperative mortality and non-recovery discharge in CCHD patients by 50% (National in-hospital mortality rate of neonatal congenital heart disease surgery in 2023: 6.5%; non-recovery discharge rate: 12.66%), thereby improving the overall level of CCHD treatment in China.",[55],"Complex Congenital Heart Disease","2026-01-15",{"date":58,"type":32},"2026-01-23",{"date":60,"type":32},"2025-12-01",{"date":62,"type":21},"2029-01-31",{"name":38,"class":39},12,""]